课题基金 / 基金详情

Point-of-Care Diagnostic Test for Entamoeba histolytica Cysts

Point-of-Care Diagnostic Test for Entamoeba histolytica Cysts
溶组织内阿米巴囊肿的护理点诊断测试
批准号:
8251565
负责人:
Joel F Herbein
金额:
$29.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-04 至 2014-05-31

项目摘要

项目成果

Joel F Herbein的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The NIAID Category B priority pathogen Entamoeba histolytica is a public health threat, especially as a cause of diarrhea in travelers to and immigrants from endemic areas, men who have sex with men, and children in the developing world where it is in the top 5 causes of severe diarrhea. It is also a biodefense threat to water and food supplies due to its resistance to chlorination and low infectious dose. Here we propose to develop a point-of-care (POC) fecal antigen diagnostic test. Successful completion of the project will produce the first POC test that detects E. histolytica in both fresh and formalin-fixe specimens]. Investigators: Dr. Herbein at TechLab is an expert in developing enteric diagnostics; having directed the FDA- clearance of diagnostics for Giardia and Cryptosporidia and having served as the PI for multiple Phase I/II SBIR/STTR projects. Dr. Petri at the University of Virginia is an international leader in clinical and basic investigation of amebiasis, and in collaboration with TechLab has developed the only FDA 510(k)-cleared diagnostic test for E. histolytica. [Innovation: Innovative aspects include: (1) development and manufacture of a POC test for amebiasis that can be multiplexed with that of other category B enteric parasites; and (2) production of the first diagnostic test for E. histolytica detection in both fresh and formalin-fixed samples]. [Approach: The following two Specific Aims are proposed to accomplish our goal of a new diagnostic test for amebiasis: 1) Produce monoclonal and polyclonal antibodies against the highly abundant "Jacob" protein of the E. histolytica cyst. 2) Apply these antibodies to produce a POC test for E. histolytica]. Environment: The proposal builds on the longstanding partnership of Dr. Petri at the University of Virginia with Dr. Herbein of TechLab, Inc. for amebiasis diagnostic test development. These two institutions are importantly only two hours apart and that have worked together successfully for over a decade. PUBLIC HEALTH RELEVANCE: Entamoeba histolytica is a biodefense threat and an important cause of diarrhea in: (a) travelers to, and immigrants from, endemic areas; (b) in men who have sex with men; and (c) in children in the developing world. We propose to produce a "point-of-care" assay for amebiasis that is rapid and easy to use, and that specifically detects E. histolytica (and not the non-pathogen E. dispar) in both fresh and fixed stool specimens.]
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Point-of-Care Diagnostic Test for Entamoeba histolytica Cysts
  • 批准号:
    8479312
  • 项目类别:
  • 资助金额:
    $29.98万
  • 财政年份:
    2012
  • 负责人:
    Joel F Herbein
  • 依托单位:
Multiplex Diagnostic for Enteric Category B Pathogens and Intestinal Biomarkers
  • 批准号:
    7803218
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2010
  • 负责人:
    Joel F Herbein
  • 依托单位:
Multiplex Diagnostic for Enteric Category B Pathogens and Intestinal Biomarkers
  • 批准号:
    8050050
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2010
  • 负责人:
    Joel F Herbein
  • 依托单位:
Multiplex Screening ELISA for Giardia, Cryptosporidium and E. histolytica
  • 批准号:
    7587339
  • 项目类别:
  • 资助金额:
    $74.63万
  • 财政年份:
    2008
  • 负责人:
    Joel F Herbein
  • 依托单位:
海外基金